Public Employees Retirement System of Ohio acquired a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 42,244 shares of the company's stock, valued at approximately $601,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TAK. Raymond James & Associates raised its position in shares of Takeda Pharmaceutical by 5.3% in the second quarter. Raymond James & Associates now owns 255,762 shares of the company's stock valued at $3,310,000 after purchasing an additional 12,862 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Takeda Pharmaceutical by 40.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 10,907 shares of the company's stock valued at $141,000 after acquiring an additional 3,143 shares during the period. Gold Investment Management Ltd. lifted its position in shares of Takeda Pharmaceutical by 2.1% during the second quarter. Gold Investment Management Ltd. now owns 71,776 shares of the company's stock worth $929,000 after acquiring an additional 1,453 shares in the last quarter. Atomi Financial Group Inc. boosted its holdings in shares of Takeda Pharmaceutical by 8.1% in the second quarter. Atomi Financial Group Inc. now owns 21,846 shares of the company's stock worth $283,000 after acquiring an additional 1,641 shares during the period. Finally, Ridgewood Investments LLC purchased a new position in shares of Takeda Pharmaceutical in the second quarter valued at $89,000. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Stock Performance
Shares of NYSE:TAK traded up $0.09 during midday trading on Friday, reaching $13.10. 1,848,702 shares of the company traded hands, compared to its average volume of 1,830,433. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The firm's fifty day moving average price is $13.70 and its two-hundred day moving average price is $13.88. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $41.68 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
